← Eichor
Study identifier: NCT07421700 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Condition: Urothelial Cancer · Advanced/Metastatic Urothelial Cancer · Urothelial Carcinoma  ·  Sponsor: Pfizer

PhasePhase 1/Phase 2
Planned participants132
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are mana…

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (115)

Highlands Oncology Group, PAFayetteville, Arkansas, United StatesRecruiting
Highlands Oncology Group, PARogers, Arkansas, United StatesRecruiting
Highlands Oncology Group, PASpringdale, Arkansas, United StatesRecruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)Duarte, California, United StatesRecruiting
City of Hope Investigational Drug Services (IDS)Duarte, California, United StatesRecruiting
City of Hope at Irvine LennarIrvine, California, United StatesRecruiting
City of Hope Investigational Drug Service (IDS)Irvine, California, United StatesRecruiting
City of Hope-Long Beach (ELM)Long Beach, California, United StatesRecruiting
City of Hope UPLANDUpland, California, United StatesRecruiting
Rocky Mountain Cancer Centers, LLPAurora, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers, LLPDenver, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers, LLPLone Tree, Colorado, United StatesRecruiting

+ 103 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07421700